Government data from Australia, the U.S., Canada, Scotland and England suggest people who have received at least two shots are now showing signs of serious immune system degradation.
This immune erosion, aka, acquired immune deficiency, is thought to account for elevated rates of myocarditis and other post-jab conditions, some of which can result in death if progressing rapidly, or chronic diseases if moving more slowly.
At this stage in the game, it’s apparent that the COVID jab no longer works. Many health officials and world leaders are even openly acknowledging that the COVID shots cannot end the pandemic and that we must learn to live with the virus.
A major driver for this U-turn in the pandemic narrative is the emergence of the Omicron variant which, by mid-January 2022, accounted for 99.5% of all COVID cases in the U.S.
The infection, which is far milder than previous ones, is ripping through populations, leaving natural herd immunity in its wake. Despite that, vaccine makers are still hard at work to produce an Omicron-specific injection. Pfizer has promised to have one ready by March 2022.
The question is why, seeing how by the time the shot is released, just about everybody will have been exposed. If natural herd immunity is already maxed out, what good could a “vaccine” possibly do?
‘EVERYONE’ WILL HAVE NATURAL IMMUNITY
As Dr. William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health told CNBC, “An omicron-targeted vaccine was needed in December [2021]. It still could be valuable but I do think in many ways, it’s too late.”
Dr. Shaun Truelove, an infectious disease epidemiologist at Johns Hopkins Bloomberg School of Public Health and a member of a team of researchers who make COVID projections, agreed, saying, “Given how quickly this [variant] is happening, [the targeted vaccine] may not matter because everybody’s going to be infected.”
Pfizer CEO Albert Bourla even admits he doesn’t know “whether or not the new vaccine is needed or how it could be used,” CNBC reports.
January 25, 2022, Pfizer and Moderna announced they’ve started enrolling adults, 18 to 55, for trials on an Omicron-specific jab in the U.S. and South Africa. Pfizer will evaluate safety, tolerability and immune response in 1,420 volunteers, some of whom will have received two doses while others will have received three already. A third cohort will be unvaccinated (although one wonders where they’ll get those from).
Moderna has also joined the pointless race to produce an Omicron booster,8 although it’s doubtful they’ll be able to produce one any faster than Pfizer.
Moderna CEO Stéphane Bancel told CNBC that a fourth COVID jab also may be on the horizon, “as the efficacy of boosters will likely decline over time.” It’s unclear what strain that fourth shot would target.
ISRAEL PROVES FAILURE OF COVID BOOSTERS
For a preview of what’s in store after third and fourth booster shots, all we have to do is look at Israel, where more than 250,000 fourth doses had already been given by early January 2022. According to CNBC:
“Early data from Israel shows that a fourth dose does increase antibody levels, says Dr. David Hirschwerk, infectious disease specialist and medical director at Northwell Health’s North Shore University Hospital.”
What CNBC neglects to note is that, after the rollout of a fourth dose, Israel now has the highest COVID case rate per capita of any country in the world since the beginning of the pandemic.
CONTINUE READING